Skip to Content
Merck
All Photos(1)

Key Documents

74137

Sigma-Aldrich

D-chiro-Inositol

≥98.0% (HPLC)

Synonym(s):

D-(+)-chiro-Inositol, 1,2,4/3,5,6-Hexahydroxycyclohexane

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C6H12O6
CAS Number:
Molecular Weight:
180.16
EC Number:
MDL number:
UNSPSC Code:
12352201
PubChem Substance ID:
NACRES:
NA.25

Quality Level

Assay

≥98.0% (HPLC)

form

solid

optical activity

[α]/D 64.0±3.0°, c = 1 in H2O

color

white

mp

230 °C (lit.)

storage temp.

2-8°C

SMILES string

O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H]1O

InChI

1S/C6H12O6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-12H/t1-,2-,3-,4-,5+,6+/m0/s1

InChI key

CDAISMWEOUEBRE-LKPKBOIGSA-N

Looking for similar products? Visit Product Comparison Guide

Application


  • D-chiro-inositol in clinical practice: An extensive review by The Experts Group on Inositol in Basic and Clinical Research presents D-chiro-inositol as a valuable substance in managing conditions like polycystic ovary syndrome, highlighting its clinical applications and potential benefits in metabolic syndrome management (Dinicola et al., 2024).

  • D-chiro-inositol enhancing longevity and antioxidant capacity: A study demonstrates that D-chiro-inositol boosts antioxidant capacity and extends lifespan in Caenorhabditis elegans through the activation of Nrf-2/SKN-1 and FOXO/DAF-16 pathways, suggesting its potential for optimizing dosage in age-related health interventions (Shi et al., 2023).

Biochem/physiol Actions

Important second messenger in insulin signal transduction.

Other Notes

To gain a comprehensive understanding of our extensive range of Monosaccharides for your research, we encourage you to visit our Carbohydrates Category page.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Hao-Han Chang et al.
Experimental biology and medicine (Maywood, N.J.), 240(1), 8-14 (2014-07-26)
Diabetic nephropathy is a serious complication of diabetes mellitus with a pressing need for effective metabolic markers to detect renal impairment. Of potential significance are the inositol compounds, myo-inositol (MI), and the less abundant stereoisomer, D-chiro-inositol (DCI), which are excreted
Alessandro D Genazzani et al.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 30(6), 438-443 (2014-03-08)
Polycystic ovary syndrome (PCOS) is a common endocrine condition that affects fertility through oligo-ovulation, hyperandrogenism and polycystic morphology of the ovaries. Since it has been demonstrated a high incidence of insulin resistance in PCOS patients, our study aimed to evaluate
J E Nestler et al.
The New England journal of medicine, 340(17), 1314-1320 (1999-04-29)
Women with the polycystic ovary syndrome have insulin resistance and hyperinsulinemia, possibly because of a deficiency of a D-chiro-inositol-containing phosphoglycan that mediates the action of insulin. We hypothesized that the administration of D-chiro-inositol would replenish stores of the mediator and
Alfonsa Pizzo et al.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 30(3), 205-208 (2013-12-20)
Myo-inositol and D-chiro-inositol are capable of improving the ovarian function and metabolism of polycystic ovary syndrome (PCOS) patients. The aim of this work is to compare the effects of myo-inositol and D-chiro-inositol in PCOS. We enrolled 50 patients, with homogeneous
Ken-ichi Yoshida et al.
Applied and environmental microbiology, 72(2), 1310-1315 (2006-02-08)
D-chiro-inositol (DCI) is a drug candidate for the treatment of type 2 diabetes and polycystic ovary syndrome, since it improves the efficiency with which the body uses insulin and also promotes ovulation. Here, we report genetic modification of Bacillus subtilis

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service